<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00913003</url>
  </required_header>
  <id_info>
    <org_study_id>STU0008753</org_study_id>
    <nct_id>NCT00913003</nct_id>
  </id_info>
  <brief_title>Analgesic Effect of Perioperative Systemic Lidocaine in Patients Undergoing Unilateral Mastectomy Surgery</brief_title>
  <official_title>Analgesic Effect of Perioperative Systemic Lidocaine in Patients Undergoing Unilateral Mastectomy Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine if perioperative systemic lidocaine administration will
      decrease the amount of opioid analgesics required in women undergoing mastectomy surgery. In
      addition, patients receiving systemic lidocaine will have a lower incidence of
      post-mastectomy pain syndrome.

      This study will have 2 groups. Participants will be randomized into one of each group. The
      first group will be administered the drug lidocaine prior to surgery and the second group
      Group B will be administered saline (salt water). This is a blinded study which means the
      participant will not know which group they have been assigned. The subjects participation
      will last 12 months (surveys post operatively).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be recruited up to 21 days prior to the day of surgery. The consent form will
      be reviewed with the patient, and the patient will be allowed to take a copy home. If the
      patient does not have an EKG within the past 6 weeks in her medical record, an EKG will be
      obtained at the time of recruitment. At the time of recruitment, the patient will be
      randomized using a computer-generated code. Group A will receive lidocaine during surgery,
      and Group B will receive saline (placebo) during surgery.The study drug will be prepared by
      the investigator(s). The anesthesiologist and research nurse will be blinded. If necessary in
      the event of an emergency, these individuals may be unblinded.

      Group A (Lidocaine):

      Induction: 1.5 mg/kg IV (IBW) bolus, administered prior to Propofol. The maximum loading dose
      administered will not exceed 150 mg IV Infusion: 33.3 mcg/kg/min IV (IBW), initiated before
      surgical incision.Discontinue infusion 1 hour after skin closure complete.No other local
      anesthetics administered intra-operatively

      Group B (Saline):

      Induction: IV bolus, administered prior to Propofol Infusion: Initiate before surgical
      incision (rate calculated as if for lidocaine infusion). Discontinue infusion 1 hour after
      skin closure complete No local anesthetics administered intra-operatively. Baseline thermal
      quantitative sensory testing (QST) scores will be obtained pre-operatively using TSA-II Neuro
      Sensory Analyzer (Medoc Advanced Medical Systems, Durham, NC).

      Baseline Modified Quality of Recovery (MQoR-40) Survey will be obtained on the morning of
      surgery.

      Preoperative anxiety, depression, and pain characterization will be measured within 24 hours
      of the time of surgery using a validated questionnaire (Hospital Anxiety and Depression
      Scale). If the questionnaire responses indicate the patient is experiencing depressive
      symptoms, the patient will be notified of the results and instructed to follow up with her
      primary care physician.

      Intraoperatively, patients will receive a standardized anesthetic (management protocol
      attached).

      Two blood samples for lidocaine levels will be obtained on subjects. The first lidocaine
      blood sample will be collected after the lidocaine/placebo bolus in the operating room. The
      second lidocaine blood sample will be obtained when the lidocaine/placebo infusion has been
      discontinued (one hour after skin closure). A total of 5 mLs of blood will be obtained.

      Patients will be examined daily by a research nurse while admitted to the hospital. Daily
      pain scores will be noted, as will complications related to the perioperative period. If the
      subject is discharged within 24 hours the research nurse will call by phone to ask the
      subject about pain 0-10 and type and amount of pain relievers used since discharge.MQoR-40
      will be administered on the day of discharge. It will be repeated at 6 weeks, 6 months, and
      12 months after surgery. Patients will complete the Mastectomy Patient Follow-Up, Modified
      LANNS Pain Scale, and McGill Pain questionnaires at 6 months and 12 months after surgery for
      detection of Post-Mastectomy Pain Syndrome (PMPS).

      The definition of PMPS will be: The presence of a dull, burning,and aching sensation in the
      anterior chest, arm, and axilla exacerbated by movement of the shoulder girdle.

      Appendix 1—Anesthetic Management Protocol Appendix 2—HADS Appendix 3—MQoR-40 Appendix
      4—Modified LANNS and McGill Appendix 5—Follow-Up Questionnaire
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI terminated employment with the University
  </why_stopped>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 Hour Hydromorphone</measure>
    <time_frame>24 hour</time_frame>
    <description>Total IV hydromorphone administered during surgery to 24 hours post surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Post Operative Nausea</measure>
    <time_frame>Immediate post operative to 48 hours</time_frame>
    <description>Nausea at any time during the post operative period for 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Post Operative Ileus</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group B using saline as a placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A lidocaine infusion and bolus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)</description>
    <arm_group_label>Lidocaine</arm_group_label>
    <other_name>Group A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Group B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-65 years

          -  Gender: Female

          -  ASA Physical Status I-III

          -  Non-pregnant

          -  Surgery: Unilateral total or segmental mastectomy

          -  Language: English speaking

          -  Consent: Obtained

        Exclusion Criteria:

          -  Age: Under 18 or over 65 years

          -  ASA Physical Status &gt;III

          -  Pregnancy

          -  Language: Non-English speaking

          -  Allergy to Lidocaine or amide local anesthetics

          -  Contraindication to succinylcholine

          -  History and/or EKG evidence of conduction defect

          -  Renal failure (Creatinine &gt;1.7 mg/dL)

          -  Patient expected to remain intubated after procedure

          -  Chronic home opioid or steroid use

          -  Opioid use within one week prior to procedure

          -  Drug or alcohol abuse

          -  Inability to use PCA
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Altman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Groudine SB, Fisher HA, Kaufman RP Jr, Patel MK, Wilkins LJ, Mehta SA, Lumb PD. Intravenous lidocaine speeds the return of bowel function, decreases postoperative pain, and shortens hospital stay in patients undergoing radical retropubic prostatectomy. Anesth Analg. 1998 Feb;86(2):235-9.</citation>
    <PMID>9459225</PMID>
  </reference>
  <reference>
    <citation>Joshi GP. Multimodal analgesia techniques and postoperative rehabilitation. Anesthesiol Clin North America. 2005 Mar;23(1):185-202. Review.</citation>
    <PMID>15763418</PMID>
  </reference>
  <reference>
    <citation>Kaba A, Laurent SR, Detroz BJ, Sessler DI, Durieux ME, Lamy ML, Joris JL. Intravenous lidocaine infusion facilitates acute rehabilitation after laparoscopic colectomy. Anesthesiology. 2007 Jan;106(1):11-8; discussion 5-6.</citation>
    <PMID>17197840</PMID>
  </reference>
  <reference>
    <citation>Koppert W, Weigand M, Neumann F, Sittl R, Schuettler J, Schmelz M, Hering W. Perioperative intravenous lidocaine has preventive effects on postoperative pain and morphine consumption after major abdominal surgery. Anesth Analg. 2004 Apr;98(4):1050-5, table of contents.</citation>
    <PMID>15041597</PMID>
  </reference>
  <reference>
    <citation>Macdonald L, Bruce J, Scott NW, Smith WC, Chambers WA. Long-term follow-up of breast cancer survivors with post-mastectomy pain syndrome. Br J Cancer. 2005 Jan 31;92(2):225-30.</citation>
    <PMID>15655557</PMID>
  </reference>
  <reference>
    <citation>McCleane G. Intravenous lidocaine: an outdated or underutilized treatment for pain? J Palliat Med. 2007 Jun;10(3):798-805. Review.</citation>
    <PMID>17592992</PMID>
  </reference>
  <reference>
    <citation>Owczuk R, Wujtewicz MA, Sawicka W, Piankowski A, Polak-Krzeminska A, Morzuch E, Wujtewicz M. The effect of intravenous lidocaine on QT changes during tracheal intubation. Anaesthesia. 2008 Sep;63(9):924-31. doi: 10.1111/j.1365-2044.2008.05525.x. Epub 2008 Jun 10.</citation>
    <PMID>18547294</PMID>
  </reference>
  <reference>
    <citation>Violet JA, Dearling JL, Green AJ, Begent RH, Pedley RB. Fractionated 131I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice. Br J Cancer. 2008 Aug 19;99(4):632-8. doi: 10.1038/sj.bjc.6604511.</citation>
    <PMID>18682714</PMID>
  </reference>
  <reference>
    <citation>Cheville AL, Tchou J. Barriers to rehabilitation following surgery for primary breast cancer. J Surg Oncol. 2007 Apr 1;95(5):409-18. Review.</citation>
    <PMID>17457830</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2009</study_first_submitted>
  <study_first_submitted_qc>June 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2009</study_first_posted>
  <results_first_submitted>January 21, 2015</results_first_submitted>
  <results_first_submitted_qc>February 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2015</results_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Christian Altman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lidocaine</keyword>
  <keyword>Mastectomy</keyword>
  <keyword>Pain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Group B using saline as a placebo.
Placebo: Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug</description>
        </group>
        <group group_id="P2">
          <title>Lidocaine</title>
          <description>Group A lidocaine infusion and bolus.
Lidocaine: Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Group B using saline as a placebo.
Placebo: Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug</description>
        </group>
        <group group_id="B2">
          <title>Lidocaine</title>
          <description>Group A lidocaine infusion and bolus.
Lidocaine: Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.4" spread="10.1"/>
                    <measurement group_id="B2" value="48.5" spread="7.9"/>
                    <measurement group_id="B3" value="49.5" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Post Operative Nausea</title>
        <description>Nausea at any time during the post operative period for 48 hours</description>
        <time_frame>Immediate post operative to 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Group B using saline as a placebo.
Placebo: Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine</title>
            <description>Group A lidocaine infusion and bolus.
Lidocaine: Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Post Operative Nausea</title>
          <description>Nausea at any time during the post operative period for 48 hours</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Post Operative Ileus</title>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Group B using saline as a placebo.
Placebo: Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine</title>
            <description>Group A lidocaine infusion and bolus.
Lidocaine: Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Post Operative Ileus</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>24 Hour Hydromorphone</title>
        <description>Total IV hydromorphone administered during surgery to 24 hours post surgery</description>
        <time_frame>24 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Group B using saline as a placebo.
Placebo: Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine</title>
            <description>Group A lidocaine infusion and bolus.
Lidocaine: Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)</description>
          </group>
        </group_list>
        <measure>
          <title>24 Hour Hydromorphone</title>
          <description>Total IV hydromorphone administered during surgery to 24 hours post surgery</description>
          <units>miligrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="1.6"/>
                    <measurement group_id="O2" value="1.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Group B using saline as a placebo.
Placebo: Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug</description>
        </group>
        <group group_id="E2">
          <title>Lidocaine</title>
          <description>Group A lidocaine infusion and bolus.
Lidocaine: Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>First degree heart block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated early because the PI left the institution.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Paul Fitzgerald</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695- 1064</phone>
      <email>p-fitzgerald2@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

